Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.56B | $830.81M | $7.85M | $54.20M | $0.53 | 16.02% | 19.35% | -57.94% | -8.80% | 2026-11-03 | ||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.16B | $463.98M | $45.39M | $28.52M | $0.21 | 76.11% | N/A | N/A | N/A | 2026-10-27 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $29.40B | $4.80B | $1.18B | $807.99M | $6.10 | 95.14% | 47.52% | N/A | N/A | 2026-10-29 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.91B | $840.85M | $119.96M | $80.66M | $1.07 | 58.85% | 155.62% | 1,683.33% | N/A | 2026-10-27 | ||
| VCEL | VERICEL CORP | $2.06B | $306.30M | $44.05M | $24.22M | $0.48 | 22.95% | 15.11% | 242.86% | 19.14% | 2026-11-05 | ||
| RPRX | ROYALTY PHARMA PLC | $32.87B | $2.54B | $1.18B | $815.00M | $1.88 | 10.01% | 2.53% | -18.97% | -5.47% | 2026-11-04 | ||
| KRYS | KRYSTAL BIOTECH INC | $9.54B | $440.48M | $233.29M | $241.47M | $8.27 | 22.63% | N/A | 61.84% | N/A | 2026-11-02 | ||
| HALO | HALOZYME THERAPEUTICS INC | $12.47B | $1.66B | $718.44M | $413.60M | $3.56 | 41.15% | 32.17% | -20.54% | 16.63% | 2026-11-02 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $593.24M | $136.07M | $77.33M | $58.26M | $0.95 | 119.40% | 36.81% | N/A | N/A | 2026-11-04 | ||
| TGTX | TG THERAPEUTICS INC | $8.31B | $799.54M | $139.21M | $441.49M | $3.08 | 76.08% | 219.17% | 651.22% | N/A | 2026-11-02 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.07B | $3.41B | $385.69M | $72.97M | $0.38 | 11.20% | 12.19% | -88.95% | -39.24% | 2026-10-26 | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.30B | $4.60B | $1.62B | $940.76M | $15.26 | 12.59% | 11.87% | N/A | 68.91% | 2026-11-04 | ||
| MDXG | MIMEDX GROUP INC | $669.04M | $355.17M | $22.81M | $6.24M | $0.04 | -2.36% | 6.36% | -81.82% | N/A | 2026-11-04 | ||
| EXEL | EXELIXIS INC | $14.47B | $2.44B | $1.09B | $860.62M | $3.29 | 9.23% | 16.06% | 53.02% | 60.39% | 2026-11-03 | ||
| ADMA | ADMA BIOLOGICS INC | $2.18B | $512.28M | $232.99M | $168.96M | $0.72 | 8.04% | 54.54% | -18.18% | N/A | 2026-11-04 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $6.04B | $290.54M | $278.98M | $197.22M | $10.07 | 54.89% | 4.89% | N/A | 28.45% | 2026-11-05 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $127.93B | $12.59B | $5.50B | $4.41B | $17.33 | 10.23% | 13.50% | 22.73% | 17.68% | 2026-11-02 | ||
| UTHR | UNITED THERAPEUTICS CORP | $23.23B | $3.15B | $1.68B | $1.31B | $30.24 | 2.49% | 14.68% | 9.25% | 23.42% | 2026-11-04 | ||
| TECH | BIO-TECHNE CORP | $11.35B | $1.22B | $347.67M | $181.86M | $1.17 | -0.38% | 5.47% | 148.94% | 5.15% | 2026-11-04 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.31B | $959.90M | $280.01M | $181.27M | $3.14 | 24.25% | 32.46% | -0.63% | 10.45% | 2026-11-03 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $75.69B | $15.53B | $5.75B | $4.33B | $41.94 | 9.29% | 4.64% | 0.43% | -6.56% | 2026-10-30 | ||
| VCYT | VERACYTE INC | $3.68B | $561.90M | $139.68M | $114.48M | $1.44 | 17.28% | 28.97% | 311.43% | N/A | 2026-11-03 | ||
| SPRO | SPERO THERAPEUTICS INC | $69.30M | $47.00M | $7.64M | $7.38M | $0.14 | -3.25% | 20.69% | N/A | N/A | 2026-11-12 | ||
| INCY | INCYTE CORP | $23.37B | $5.82B | $2.07B | $1.61B | $8.12 | 26.93% | 16.42% | 83.71% | 39.45% | 2026-10-27 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.